Development of treatment strategy for CKD-MBD by multilateral mechanism of ethelcarcitrate hydrochloride
- Conditions
- Secondary hyperparathyroidism
- Registration Number
- JPRN-UMIN000030392
- Lead Sponsor
- agoya University Graduate School of Medicine, Nephrology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 120
Not provided
1.patients who have been prescribed etelcalcetide before 2.bisphosphonate users within 24 weeks 3.primary hyperparathyroidism 4.undergoing parathyroidectomy or intervention therapy to parathyroid within 90 days before enrollment 5.scheduled parathyroidectomy, intervention therapy to parathyroid or kidney plantation 6. pregnant or breast feeding 7. patients who are deemed unsuitable by a physician, for instance cancer, severe infection and severe complication 8. patients who are prescribed Maxacalcitol, over 10[micro]gx3/week at obtainment of IC 9. patients who are prescribed Calcitriol, over 0.75[micro]gx3/week at obtainment of IC 10. patients who are prescribed other active VitD, over half of maximum dose at obtainment of IC 11. patients who are prescribed precipitated calcium carbonate, over 3g/day at obtainment of IC
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ratio of achievement of more than 50% reduction and under 240pg/dl in intact parathyroid hormone (iPTH) after 12 weeks of treatment
- Secondary Outcome Measures
Name Time Method